GABAergic hypotheses of anxiety and depression: Focus on GABAB receptors

Drugs of Today

Volumn 41, Issue 11, 2005, Pages 755-766

  Pilc, Andrzej ^a,b   Nowak, Gabriel ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYSACLOFEN; 3 [1 [3 [(CYCLOHEXYLMETHYL)HYDROXYPHOSPHINYL] 2 HYDROXYPROPYLAMINO]ETHYL]BENZOIC ACID; 3 [1 [[2 HYDROXY 3 [HYDROXY(4 METHOXYBENZYL)PHOSPHINYL]PROPYL]AMINO]ETHYL]BENZOIC ACID; 3 AMINOPROPANEPHOSPHINIC ACID; 3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 3 AMINOPROPYL(METHYL)PHOSPHINIC ACID; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 5,5 DIMETHYL 2 MORPHOLINEACETIC ACID; [3 (3,4 DICHLOROBENZYLAMINO)PROPYL](DIETHOXYMETHYL)PHOSPHINIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BENZYL[3 [[1 (3,4 DICHLOROPHENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]PHOSPHINIC ACID; CGP 44532; CGP 46999A; CGP 51176; CGP 54626; CGP 56433A; CGP 56999A; CGP 61334; CITALOPRAM; DESIPRAMINE; FLUOXETINE; GS 39783; IMIPRAMINE; MAPROTILINE; NCS 382; PHACLOFEN; SACLOFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILOXAZINE;

ALLOSTERISM; ANIMAL BEHAVIOR; ANXIETY DISORDER; CHRONOPHARMACOLOGY; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG RECEPTOR BINDING; GABAERGIC TRANSMISSION; HUMAN; MAZE TEST; MOLECULAR CLONING; NONHUMAN; PREVALENCE; PSYCHOPHARMACOLOGY; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SECOND MESSENGER; TRANQUILIZING ACTIVITY;

ALLOSTERIC REGULATION; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BRAIN; CLINICAL TRIALS; DEPRESSIVE DISORDER; GABA AGONISTS; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, MOLECULAR; RECEPTORS, GABA-A; RECEPTORS, GABA-B; SYNAPTIC TRANSMISSION;

EID: 30444441081     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.11.904728     Document Type: Review

References (89)

1. Murray, C.J., Lopez, A.D. Alternative projections of mortality by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349: 1498-504.
2. Vos, T., Mathers, C.D. The burden of mental disorders: A comparison of methods between the Australian Burden of Disease studies and the Global Burden of Disease study. Bull World Health Organ 2000, 78: 427-38.
3. Barrett, J.E., Barrett, J.A., Oxman, I.E. et al. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988, 45: 1100-6.
4. Andrews, G., Sanderson, K., Slade, T. et al. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull World Health Organ 2000, 78: 446-54.
5. Nutt, D.J., Ballenger, J.C., Sheehan, D. et al. Generalized anxiety disorder: Comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol 2002, 5: 315-25.
6. Zimmerman, M., McDermut, W., Mattia, J.I. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry 2000, 157: 1337-40.
7. Sternbach, L.H. The discovery of librium. Agents Actions 1972, 2: 193-6.
8. Stahl, S.M. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 2002, 63: 756-7.
9. Paredes, R.G., Agmo, A. GABA and behavior: The role of receptor subtypes. Neurosci Biobehav Rev 1992, 16: 145-70.
10. Petty, F. GABA and mood disorders: A brief review and hypothesis. J Affective Disord 1995, 34: 275-81.
11. Kaufman, D.L., Houser, C.R., Tobin, A.J. Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem 1991, 56: 720-3.
12. Schousboe, A. Pharmacological and functional characterization of astrocytic GABA transport: A short review. Neurochem Res 2000, 25: 1241-4.
13. Waagepetersen, H.S., Qu, H., Hertz, L. et al. Demonstration of pyruvate recycling in primary cultures of neocortical astrocytes but not in neurons. Neurochem Res 2002, 27: 1431-7.
14. Waagepetersen, H.S., Sonnewald, U., Schousboe, A. Compartmentation of glutamine, glutamate, and GABA metabolism in neurons and astrocytes: Functional implications. Neuroscientist 2003, 9: 398-403.
15. Bormann, J. The 'ABC' of GABA receptors. Trends Pharmacol Sci 2000, 21: 16-9.
16. Chebib, M., Johnston, G.A. The 'ABC' of GABA receptors: A brief review. Clin Exp Pharmacol Physiol 1999, 26: 937-40.
17. Rudolph, U., Crestani, F., Mohler, H. GABA(A) receptor subtypes: Dissecting their pharmacological functions. Trends Pharmacol Sci 2001, 22: 188-94.
18. Hill, D.R., Bowery, N.G. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature 1981, 290: 149-52.
19. Kaupmann, K., Huggel, K., Heid, J. et al. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997, 386: 239-46.
20. Kaupmann, K., Malitschek, B., Schuler, V. et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 1998, 396: 683-7.
21. Marshall, F.H., Jones, K.A., Kaupmann, K. et al. GABAB receptors -The first 7TM heterodimers. Trends Pharmacol Sci 1999, 20: 396-9.
22. Bowery, N.G. GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol 1993, 33: 109-47.
23. Thuault, S.J., Brown, J.T., Sheardown, S.A. et al. The GABA(B2) subunit is critical for the trafficking and function of native GABA(B) receptors. Biochem Pharmacol 2004, 68: 1655-66.
24. Fritschy, J.M., Meskenaite, V., Weinmann, O. et al. GABAB-receptor splice variants GB1a and GB1b in rat brain: Developmental regulation, cellular distribution and extrasynaptic localization. Eur J Neurosci 1999, 11: 761-8.
25. Margeta-Mitrovic, M., Mitrovic, I., Riley, R.C. et al. Immunohistochemical localization of GABA (B) receptors in the rat central nervous system. J Comp Neurol 1999, 405: 299-321.
26. Calver, A.R., Medhurst, A.D., Robbins, M.J. et al. The expression of GABA(B1) and GABA (B2) receptor subunits in the CNS differs from that in peripheral tissues. Neuroscience 2000, 100: 155-70.
27. Luscher, C., Jan, L.Y., Stoffel, M. et al. G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 1997, 19: 687-95.
28. Bowery, N.G., Bettler, B., Froestl, W. et al. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: Structure and function. Pharmacol Rev 2002, 54: 247-64.
29. Hudgson, P., Weightman, D. Baclofen in the treatment of spasticity. BMJ 1971, 4: 15-7.
30. Sanders, S.K., Shekhar, A. Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav 1995, 52: 701-6.
31. Nastiti, K., Benton, D., Brain, PF. The effects of compounds acting at the benzodiazepine receptor complex on the ultrasonic calling of mouse pups. Behav Pharmacol 1991, 2: 121-8.
32. Andrews, N., File, S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 1993, 235: 109-12.
33. Shephard, R.A., Wedlock, P., Wilson, N.E. Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol Biochem Behav 1992, 41: 651-3.
34. Ketelaars, C.E., Bollen, E.L., Rigter, H. et al. GABA-B receptor activation and conflict behaviour. Life Sci 1988, 42: 933-42.
35. Quintero, S., Henney, S., Lawson, P. et al. The effects of compounds related to gamma-aminobutyrate and benzodiazepine receptors on behavioural responses to anxiogenic stimuli in the rat: Punished barpressing. Psychopharmacology 1985, 85: 244-51.
36. Zarrindast, M., Rostami, P., Sadeghi-Hariri, M. GABA(A) but not GABA(B) receptor stimulation induces antianxiety profile in rats. Pharmacol Biochem Behav 2001, 69: 9-15.
37. Umezu, T. Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn J Pharmacol 1999, 80: 111-8.
38. Dalvi, A., Rodgers, R.J. GABAergic influences on plus-maze behaviour in mice. Psychopharmacology 1996, 128: 380-97.
39. Agmo, A., Pruneda, R., Guzman, M. et al. GABAergic drugs and conflict behavior in the rat: Lack of similarities with the actions of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol 1991, 344: 314-22.
40. Hinderer, S.R. The supraspinal anxiolytic effect of baclofen for spasticity reduction. Am J Phys Med Rehabil 1990, 69: 254-8.
41. Addolorato, G., Caputo, F., Capristo, E. et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol Alcohol 2002, 37: 504-8.
42. Breslow, M.F., Fankhauser, M.P., Potter, R.L. et al. Role of gamma-aminobutyric acid in antipanic drug efficacy. Am J Psychiatry 1989, 146: 353-6.
43. Drake, R.G., Davis, L.L., Cates, M.E. et al. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother 2003, 37: 1177-81.
44. Conigrave, A.D., Franks, A.M. Allosteric activation of plasma membrane receptors - physiological implications and structural origins. Prog Biophys Mol Biol 2003, 81: 219-40.
45. Jensen, A.A., Spalding, T.A. Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci 2004, 21: 407-20.
46. Urwyler, S., Pozza, M.F., Lingenhoehl, K. et al. N,N′- Dicyclopentyl-2-methylsulfanyl-5-nitropyrimidine-4,6-diamine (GS39783) and structurally related compounds: Novel allosteric enhancers of gamma-aminobutyric acid B receptor function. J Pharmacol Exp Ther 2003, 307: 322-30.
47. Mombereau, C., Kaupmann, K., Froestl, W. et al. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004, 29: 1050-62.
48. Cryan, J.F., Kelly, P.M., Chaperon, F. et al. Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N′-di cyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): Anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 2004, 310: 952-63.
49. Froestl, W., Mickel, S.J., Hall, R.G. et al. Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem 1995, 38: 3297-312.
50. Kerr, D.I., Ong, J., Prager, R.H. et al. Phaclofen: A peripheral and central baclofen antagonist. Brain Res 1987, 405: 150-4.
51. Kerr, D.I., Ong, J., Johnston, G.A. et al. Antagonism at GABAB receptors by saclofen and related sulphonic analogues of baclofen and GABA. Neurosci Lett 1989, 107: 239-44.
52. Kerr, D.I., Ong, J., Johnston, G.A. et al. 2-Hydroxy-saclofen: An improved antagonist at central and peripheral GABAB receptors. Neurosci Lett 1988, 92: 92-6.
53. Froestl, W., Mickel, S.J., von Sprecher, G. et al. Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J Med Chem 1995, 38: 3313-31.
54. Froestl, W., Gallagher, M., Jenkins, H. et al. SGS742: The first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol 2004, 68: 1479-87.
55. Mondadori, C., Jaekel, J., Preiswerk, G. CGP 36742: The first orally active GABAB blocker improves the cognitive performance of mice, rats, and rhesus monkeys. Behav Neural Biol 1993, 60: 62-8.
56. Pile, A., Lloyd, K.G. Chronic antidepressants and GABA "B" receptors: A GABA hypothesis of antidepressant drug action. Life Sci 1984, 35: 2149-54.
57. Lloyd, K.G., Thuret, F., Pile, A. Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: A common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 1985, 235: 191-9.
58. Pratt, G.D., Bowery, N.G. Repeated administration of desipramine and a GABAB receptor antagonist, CGP 36742, discretely up-regulates GABAB receptor binding sites in rat frontal cortex. Br J Pharmacol 1993, 110: 724-35.
59. Szekely, A.M., Barbaccia, M.L., Costa, E. Effect of a protracted antidepressant treatment on signal transduction and [3H](-)-baclofen binding at GABAB receptors. J Pharmacol Exp Ther 1987, 243: 155-9.
60. Gray, J.A., Green, A.R. Increased GABAB receptor function in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shocks. Br J Pharmacol 1987, 92: 357-62.
61. Suzdak, P.D., Gianutsos, G. Effect of chronic imipramine or baclofen on GABA-B binding and cyclic AMP production in cerebral cortex. Eur J Pharmacol 1986, 131: 129-33.
62. Lloyd, K.G., Pichat, P. GABA synapses, depression and antidepressant drugs. In: Dahl, E., Gram, L.F., Paul, S.M., Potter, W.Z. (Eds.). Clinical Psychopharmacology in Psychiatry. Springer-Verlag, Berlin-Heidelberg, 1987, 113-26.
63. Johnson, D.A. Drug-induced psychiatric disorders. Drugs 1981, 22: 57-69.
64. Whitlock, F.A., Evans, L.E. Drugs and depression. Drugs 1978, 15: 53-71.
65. Cross, J.A., Horton, R.W. Are increases in GABAB receptors consistent findings following chronic antidepressant administration? Eur J Pharmacol 1987, 141: 159-62.
66. Cross, J.A., Horton, R.W. Effects of chronic oral administration of the antidepressants, desmethylimipramine and zimelidine on rat cortical GABAB binding sites: A comparison with 5-HT2 binding site changes. Br J Pharmacol 1988, 93: 331-6.
67. McManus, D.J., Greenshaw, A.J. Differential effects of antidepressants on GABAB and beta-adrenergic receptors in rat cerebral cortex. Biochem Pharmacol 1991, 42: 1525-8.
68. Sands, S.A., Reisman, S.A., Enna, S.J. Effect of antidepressants on GABA(B) receptor function and subunit expression in rat hippocampus. Biochem Pharmacol 2004, 68: 1489-95.
69. Gray, J.A., Goodwin, G.M., Heal, D.J. et al. Hypothermia induced by baclofen, a possible index of GABAB receptor function in mice, is enhanced by antidepressant drugs and ECS. Br J Pharmacol 1987, 92: 863-70.
70. Sands, S.A., Reisman, S.A., Enna, S.J. Effects of stress and tranylcypromine on amphetamine-induced locomotor activity and GABA(B) receptor function in rat brain. Life Sci 2003, 72: 1085-92.
71. Sands, S.A., McCarson, K.E., Enna, S.J. Relationship between the antinociceptive response to desipramine and changes in GABA (B) receptor function and subunit expression in the dorsal horn of the rat spinal cord. Biochem Pharmacol 2004, 67: 743-9.
72. Lehmann, A., Mattsson, J.P., Edlund, A. et al. Effects of repeated administration of baclofen to rats on GABAB receptor binding sites and subunit expression in the brain. Neurochem Res 2003, 28: 387-93.
73. Malcangio, M., Da Silva, H., Bowery, N.G. Plasticity of GABAB receptor in rat spinal cord detected by autoradiography. Eur J Pharmacol 1993, 250: 153-6.
74. Leonard, B.E. The olfactory bulbectomized rat as a model of depression. Pol J Pharmacol Pharm 1984, 36: 561-9.
75. Delini-Stula, A., Vassout, A. Influence of baclofen and GABA-mimetic agents on spontaneous and olfactory-bulb-ablation-induced muricidal behaviour in the rat. Arzneimittelforschung 1978, 28: 1508-9.
76. Lloyd, K.G., Morselli, P.L., Depoortere, H. et al. The potential use of GABA agonists in psychiatric disorders: Evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 1983, 18: 957-66.
77. Lloyd, G.K., Morselli, P.L., Bartholini, G. GABA and affective disorders. Medical Biology 1987, 65: 159-65.
78. Musch, B. The antidepressant activity of fengabine: A critical review of the present results in open clinical studies. In: Bartholini, G., Lloyd, K.G., Morselli, P.L. (Eds.). GABA and Mood Disorders. Raven, New York, 1986, 171-7.
79. Thaker, G.K., Moran, M., Tamminga, C.A. GABAmimetics: A new class of antidepressant agents? Arch Gen Psychiatry 1990, 47: 287-8.
80. Nakagawa, Y., Ishima, T., Ishibashi, Y. et al. Involvement of GABA(B) receptor systems in action of antidepressants: Baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 1996, 709: 215-20.
81. Borsini, F., Evangelista, S., Meli, A. Effect of GABAergic drugs in the behavioral 'despair' test in rats. Eur J Pharmacol 1986, 121: 265-8.
82. Nakagawa, Y., Sasaki, A., Takashima, T. The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol 1999, 381: 1-7.
83. Nakagawa, Y., Ishima, T., Ishibashi, Y. et al. Involvement of GABA(B) receptor systems in action of antidepressants. 2. Baclofen attenuates the effect of desipramine whereas muscimol has no effect in learned helplessness paradigm in rats. Brain Res 1996, 728: 225-30.
84. Nakagawa, Y., Ishima, T., Ishibashi, Y. et al. Involvement of GABA(B) receptor systems in experimental depression: Baclofen but not bicuculline exacerbates helplessness in rats. Brain Res 1996, 741: 240-5.
85. Slattery, D.A., Desrayaud, S., Cryan, J.F. GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. J Pharmacol Exp Ther 2005, 312: 290-6.
86. Bittiger, H., Froestl, W., Gentsch, C. et al. GABAB receptor antagonists: Potential therapeutic applications. 1996, 279-305.
87. Petty, F., Trivedi, M.H., Fulton, M. et al. Benzodiazepines as antidepressants: Does GABA play a role in depression? Biol Psychiatry 1995, 38: 578-91.
88. Ballenger, J.C. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 2004, 65: 1696-707.
89. Nutt, D.J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005, 10: 49-56.